Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0699790 (colon cancer)
 28,837 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The presence of occult micrometastases at the time of radical cystectomy leads to both distant and local failure in patients with locally advanced transitional cell carcinoma of the bladder. Cisplatin-based chemotherapy produces responses in 40-60% of patients with metastatic bladder cancer. Perioperative administration of chemotherapy in bladder cancer patients theoretically can impart the same survival benefits demonstrated in patients with breast, lung and colon cancer. Both neoadjuvant and adjuvant therapy have been evaluated in patients with locally advanced bladder cancer. Studies evaluating adjuvant chemotherapy have been limited by inadequate statistical power to detect meaningful clinical answers, as well as experimental arms utilizing inadequate chemotherapy. Two randomized clinical trials have demonstrated a survival benefit for neoadjvuant CMV (Cisplatin, Methotrexate, Vinblastine) or MVAC (methotrexate, vinblastine, adriamycin, cisplatin). The aggregate of available evidence suggests that neoadjuvant cisplatin-based combination chemotherapy should be considered a standard of care for patients with muscle-invasive/locally advanced operable bladder cancer. However, some physicians prefer to defer chemotherapy until after surgery, when pathologic stage is defined, as well as the risk of relapse. In patients who are either unfit for or refuse radical cystectomy, neoadjuvant chemotherapy with or without radiation can render bladder preservation possible in patients who attain pathologic major response.
 ...
PMID:Perioperative chemotherapy for bladder cancer. 1599 Mar 29

Multiple synchronous malignancies are believed to be quite rare and their diagnosis and treatment are very challenging for physicians. Co-presence of synchronous bladder and prostate cancers in an elderly individual is not uncommon; however, the simultaneous occurrence of the third cancer - colon cancer - is extremely outlandish. In the present study, the case of an 82-year-old man with a complaint of hematuria is reported who was eventually diagnosed with three synchronous cancers: stage-3 transitional cell carcinoma of the bladder, stage-4 prostate mucinous adenocarcinoma, and stage-3 glandular adenocarcinoma of the colon. The patient underwent total colectomy and radical cystoprostatectomy followed by chemotherapy and radiotherapy. The 2-year follow-up showed promising results with no major complications and the patient's general condition was satisfactory. Although synchronous cancers are not so common, they should not be disregarded in elderly patients especially in those with multiple symptoms.
 ...
PMID:The First Report of Triple Advanced Synchronous Cancer: Bladder Transitional Cell Carcinoma and Clinically Silent Adenocarcinoma of Prostate and Colon. 3181 71